Though IL1 inhibitors have been linked to increased risk of serious infections, there is a dose effect specifically warning against high doses (⩾100 mg of anakinra).[70] While no increase in adverse outcomes during pregnancy and breastfeeding has been reported,[71] more data is needed. Here, IL1A is linked to infection.